Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus TECHNETIUM TC 99M MEDRONATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus TECHNETIUM TC 99M MEDRONATE KIT.
INDIUM IN 111 CHLORIDE vs TECHNETIUM TC-99M MEDRONATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Technetium Tc-99m medronate (MDP) is a bone-seeking radiopharmaceutical that binds to calcium ions in hydroxyapatite crystals of bone. Uptake is proportional to osteoblastic activity and regional blood flow, allowing scintigraphic imaging of skeletal structures.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
Intravenous injection: 370-1110 MBq (10-30 mCi) for bone imaging. Adult dose is administered once for each imaging procedure.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Terminal elimination half-life: 6.02 hours (range 5.8–6.3 hours) in patients with normal renal function; prolonged in renal impairment.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Renal: approximately 50% of injected dose excreted unchanged in urine within 24 hours. Biliary/fecal: less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical